Pharmacokinetics of Peptides

Pharmacokinetics (PK) describes what the body does to a drug: how it absorbs, distributes, metabolizes, and eliminates it. Peptides follow different PK rules than small-molecule drugs, and understanding these differences is essential for interpreting dosing protocols and half-life data.

Absorption

Most therapeutic peptides are administered by injection because oral bioavailability is <1% for unmodified peptides. The three common injection routes differ in absorption kinetics:

• Intravenous (IV): 100% bioavailability, immediate peak. Used for Cerebrolysin, kisspeptin research, and emergency peptides
• Subcutaneous (SC): bioavailability typically 60–80%. Absorption is slower, with peak plasma levels at 1–4 hours depending on the peptide's molecular weight and formulation. This is the default route for most self-administered peptides
• Intramuscular (IM): bioavailability 75–100%. Faster absorption than SC due to higher muscle blood flow. Used for Thymalin and some clinical peptide protocols

Intranasal delivery (Semax, Selank, oxytocin) achieves 10–50% bioavailability and partially bypasses the blood-brain barrier via the olfactory epithelium.

Distribution

Peptides distribute primarily in the extracellular fluid. Unlike lipophilic small molecules, most peptides do not cross cell membranes passively — they rely on receptor-mediated endocytosis or stay in the extracellular/plasma compartment.

Volume of distribution (Vd) for most peptides is small (0.1–0.3 L/kg), reflecting confinement to plasma and interstitial fluid. Exceptions exist: lipidated peptides (semaglutide) bind albumin and achieve wider distribution, and some peptides (kisspeptin, GnRH analogs) concentrate in target tissues via receptor-mediated uptake.

Metabolism

Peptides are metabolized by ubiquitous proteolytic enzymes — not primarily by the liver's cytochrome P450 system. This means:

• No CYP drug interactions: peptides generally don't interact with CYP-metabolized drugs
• Rapid proteolysis: endopeptidases and exopeptidases in plasma, kidney, liver, and tissues break peptides into fragments within minutes to hours
• First-pass metabolism is extreme: oral peptides face hepatic + intestinal proteases

Half-life and engineering strategies

Unmodified peptides have short half-lives — often minutes to a few hours:

| Peptide | Half-life | Route |

|---|---|---|

| GnRH | 2–4 minutes | IV |

| Kisspeptin-10 | ~28 minutes | IV |

| BPC-157 | ~4 hours | SC (animal data) |

| Ipamorelin | ~2 hours | SC |

| Semaglutide | ~7 days | SC |

Semaglutide's remarkably long half-life (~168 hours vs ~4 minutes for native GLP-1) results from three engineering modifications:

1. Fatty acid acylation: a C18 fatty diacid chain enables albumin binding (>99% bound), shielding the peptide from proteolysis
2. Amino acid substitution: Aib at position 8 blocks DPP-4 cleavage
3. Linker optimization: the spacer between the peptide and fatty acid was optimized across generations

Similar strategies (PEGylation, Fc fusion, lipidation, cyclization) are used to extend half-lives of other therapeutic peptides.

Elimination

Peptides are eliminated primarily through:

• Proteolytic degradation: the dominant pathway — enzymatic cleavage into amino acids that enter normal metabolic pools
• Renal filtration: small peptides (<5 kDa) are freely filtered by the glomerulus and degraded by brush border peptidases in the proximal tubule
• Receptor-mediated clearance: target-receptor binding followed by internalization and lysosomal degradation

Hepatic clearance plays a minor role for most peptides (unlike small molecules). This means peptide doses generally do not need adjustment for mild-to-moderate hepatic impairment, though renal impairment can significantly affect clearance of small peptides.

Practical implications

• Short half-lives require frequent dosing: BPC-157 (1–2× daily), Ipamorelin (1–2× daily)
• Long-acting analogs enable weekly dosing: semaglutide (1× weekly), CJC-1295-DAC (1× weekly)
• Timing relative to meals matters for SC injections: absorption from the SC depot is affected by local blood flow, which increases after meals and exercise
• Injection site rotation prevents depot effects: repeated injection at the same site can cause lipodystrophy, altering absorption kinetics